Vyripharm Overview
- Year Founded
-
2014
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$300M
- Investors
-
1
Vyripharm General Information
Description
Developer of a biopharmaceutical innovator intended to focus on integrating traditional and alternative medicine. The company develops drugs to target cancer, drug addiction, and metabolic diseases and aims in improving clinical management through diagnosis and treatment with botanicals, synthetic pharmaceuticals, and drug delivery systems, enabling patients to cure infectious diseases, neurological disorders, and cancer.
Contact Information
Website
www.vyripharmbio.comCorporate Office
- 2405 Almeda Road
- Suite 300591
- Houston, TX 77054
- United States
Corporate Office
- 2405 Almeda Road
- Suite 300591
- Houston, TX 77054
- United States
Vyripharm Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 28-Oct-2021 | $300M | Completed | Generating Revenue | ||
| 2. Angel (individual) | 02-Aug-2016 | Cancelled | Generating Revenue | |||
| 1. Accelerator/Incubator | 16-May-2016 | Completed | Generating Revenue |
Vyripharm Patents
Vyripharm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220305145-A1 | Compositions and methods for diagnosing viral infections including covid-19 and for infection severity monitoring as well as targeted detection of cytokine storm | Inactive | 26-Mar-2021 | ||
| WO-2022204416-A1 | Compositions and methods for diagnosing viral infections including covid-19 and for infection severity monitoring as well as targeted detection of cytokine storm | Inactive | 26-Mar-2021 | ||
| US-20220370650-A1 | Formulations and kits for the diagnostic evaluation of infectious diseases and methods thereof | Inactive | 26-Mar-2021 | ||
| WO-2022204414-A1 | Formulations and kits for the diagnostic evaluation of infectious diseases and methods thereof | Inactive | 26-Mar-2021 | ||
| US-20220305148-A1 | Natural cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases | Inactive | 26-Mar-2021 | A61K51/0497 |
Vyripharm Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Texas Medical Center | Venture Capital | Minority |
Vyripharm Investments (1)
Vyripharm’s most recent deal was a Joint Venture with Pharmaceutical cannabinoids research JV (Alamo CBD/Vyripharm Enterprises). The deal was made on 03-Jan-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pharmaceutical cannabinoids research JV (Alamo CBD/Vyripharm Enterprises) | 03-Jan-2017 | Joint Venture | Other Pharmaceuticals and Biotechnology |
Vyripharm FAQs
-
When was Vyripharm founded?
Vyripharm was founded in 2014.
-
Where is Vyripharm headquartered?
Vyripharm is headquartered in Houston, TX.
-
What industry is Vyripharm in?
Vyripharm’s primary industry is Drug Discovery.
-
Is Vyripharm a private or public company?
Vyripharm is a Private company.
-
What is Vyripharm’s current revenue?
The current revenue for Vyripharm is .
-
How much funding has Vyripharm raised over time?
Vyripharm has raised $300M.
-
Who are Vyripharm’s investors?
Texas Medical Center has invested in Vyripharm.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process